Download our app Order a test

Developing and providing personalised cancer tests for doctors and patients

More about RGCC

Information for patients

We work with cancer patients to provide a range of personalised tests so you can choose the best treatment.

More patient information

Cancer tests

New methods and reliable tests to help deliver personalised treatment


RGCC CAMBISeq® (cancer analysis, mutational burden and instability sequencing) provides next generation sequencing analysis on both DNA and RNA to help predict a patient’s response to immunotherapy and to detect variants.

View test

Array comparative genomic hybridisation (aCGH) RGCC

This test identifies chromosomal abnormalities – when either part of the genetic sequence in a chromosome is deleted or added to – that might lead to cancer. It uses a technique called array CGH to identify abnormalities in a genome more clearly than traditional microscopes can. These abnormalities could be linked with parts of regions […]

View test


This test focuses on the status of a patient’s immune system. The test uses specific cellular markers, and the production of proteins called cytokines, to detect the type or types of cells that are responsible for switching a patient’s immune system on and off. Immune-Frame uses two different assays: the ELISA assay is used to […]

View test

Metastat RGCC

This test provides information, based on the detection of circulating tumour cells, about whether and where the tumour is likely to spread. Studies show that the cancer cells that have the potential to spread from the primary tumour express specific genes and proteins, or markers. These markers vary according to the organ that the tumour […]

View test


This test relies on pharmacogenomics. This is the science of inherited variations in genes, how these inherited variations dictate a patient’s response to a drug, and the ways these variations can be used to predict whether a patient will have a good or bad response to a drug, or no response at all. ChemoSNiP tests […]

View test

Onconomics Extracts

This test provides information about the efficacy of natural biological substances or extracts on circulating tumour cells. Onconomics Extracts focuses on testing using three methods: testing for the direct effect of an anti-cancer treatment, stimulating the immune system and inhibiting proliferative signals in the cancer cells that stimulate them to grow.

View test

Onconomics Plus RGCC

This test provides information about the effect of specific anti-cancer drugs, targeted therapies and natural treatments on the cancer cells in an individual patient. The test combines a molecular and a cellular approach by incorporating two procedures: epigenetic analysis and viability assays. Onconomics Plus RGCC is based on three methods: testing for the direct effect […]

View test

Onconomics RGCC

This test provides information about the effect of specific anti-cancer drugs and targeted therapies on a single patient. The test combines a molecular and a cellular approach by incorporating two procedures: epigenetic analysis and viability assays.

View test

Oncotrail RGCC

This test provides information about the presence of circulating tumour cells, their concentration, and immunophenotype for specific types of malignancies. This test is a tailor-made test for certain cancers: such as breast cancer (for which we provide the Oncotrail RGCC for breast cancer) and prostate cancer (for which we provide Oncotrail RGCC for prostate cancer. […]

View test

Oncotrace RGCC

This test provides information about the presence of circulating tumour cells, and their concentration and immunophenotype, which may help identify their origin. It is used to provide guidance about a patient’s prognosis, and to help identify the primary tumour when this is unknown.

View test

Oncocount RGCC

This test detects the presence of circulating tumour cells, and measures their concentration in the blood. As these cells that could lead to the recurrence of a cancer, this test is useful to detect relapse early, and as a follow-up tool.

View test
See all RGCC tests

Use our ‘smart filter’ to identify which test is best for your patients

Find out more

News & events

Find out more about our latest research, trials and education days

Cancer mutation test could improve early disease detection

Researchers have developed a new method for assessing whether genetic mutations, passed from parent to child, increase cancer risk. They have identified 1146 genes, called cancer heritability genes (CHGs) that may increase a person’s likelihood of developing cancer during life. The new test could improve early diagnosis and the development of better-targeted treatments for patients. […]

Read more

Scientists develop improved cancer biomarkers

Researchers have developed a new method for identifying biomarkers that could improve diagnosis and improve outcomes for patients. The Cell Heterogeneity-Adjusted cLonal Methylation (CHALM) method developed by scientists enables them to identify biomarkers that may be missed by traditional techniques, potentially leading to more accurate tests for diagnosing cancer. DNA methylation is a genetic process […]

Read more

New combination immunotherapy delivers knockout blow to lung cancer

Scientists have discovered that combining two existing forms of immunotherapy together is more effective at treating lung cancer. Working together, the two therapies deliver a one-two punch, targeting and then destroying lung tumour cells. The two-step therapy uses a patients’ immune cells to fight cancer. Scientists extract these “natural killers” from a patients’ tumour or […]

Read more

Scientists identify nine genes associated with breast cancer risk

In the biggest research project of its type ever completed, a European research team has analysed DNA samples from over 100,000 women and identified nine specific genes associated with breast cancer risk. Scientists and experts believe findings could help improve screening and the development of new, personalised treatments for the disease. In an incredible and […]

Read more

CTCs can play a key role in improving metastatic breast cancer treatment

Circulating tumour cells (CTCs) can play a crucial role in improving treatments for metastatic breast cancer, scientists have found. The simple blood test can provide clinicians with a reliable predictor of whether a treatment will be successful in less than a month, an audience at the 2020 San Antonio Breast Cancer Symposium heard in December. […]

Read more

Global Presence

RGCC operates in 23 countries across the world, with bases in all five continents.

Find out more